Evaluation of the diagnostic accuracy of a new point-of-care rapid test for SARS-CoV-2 virus detection.


Journal

Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741

Informations de publication

Date de publication:
21 12 2020
Historique:
received: 19 10 2020
accepted: 30 11 2020
entrez: 22 12 2020
pubmed: 23 12 2020
medline: 31 12 2020
Statut: epublish

Résumé

The easy access to a quick diagnosis of coronavirus disease 2019 (COVID-19) is a key point to improve the management of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and to contain its spread. Up to now, laboratory real-time PCR is the standard of care, but requires a fully equipped laboratory and significant infrastructure. Consequently, new diagnostic tools are required. In the present work, the diagnostic accuracy of the point-of-care rapid test "bKIT Virus Finder COVID-19" (Hyris Results obtained with the Hyris Kit are the same as that of standard laboratory-based real time PCR methods for all the analyzed samples. In addition, the Hyris Kit provides the test results in less than 2 h, a significantly shorter time compared to the reference methods, without the need of a fully equipped laboratory. To conclude, the Hyris kit represents a promising tool to improve the health surveillance and to increase the capacity of SARS-CoV-2 testing.

Sections du résumé

BACKGROUND
The easy access to a quick diagnosis of coronavirus disease 2019 (COVID-19) is a key point to improve the management of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and to contain its spread. Up to now, laboratory real-time PCR is the standard of care, but requires a fully equipped laboratory and significant infrastructure. Consequently, new diagnostic tools are required.
METHODS
In the present work, the diagnostic accuracy of the point-of-care rapid test "bKIT Virus Finder COVID-19" (Hyris
RESULTS
Results obtained with the Hyris Kit are the same as that of standard laboratory-based real time PCR methods for all the analyzed samples. In addition, the Hyris Kit provides the test results in less than 2 h, a significantly shorter time compared to the reference methods, without the need of a fully equipped laboratory.
CONCLUSIONS
To conclude, the Hyris kit represents a promising tool to improve the health surveillance and to increase the capacity of SARS-CoV-2 testing.

Identifiants

pubmed: 33349261
doi: 10.1186/s12967-020-02651-y
pii: 10.1186/s12967-020-02651-y
pmc: PMC7752099
doi:

Types de publication

Evaluation Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

488

Références

Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Viruses. 2020 May 26;12(6):
pubmed: 32466458
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
World J Clin Cases. 2020 Sep 26;8(18):3920-3933
pubmed: 33024749
Clin Chim Acta. 2020 Jun;505:172-175
pubmed: 32156607
Front Cell Dev Biol. 2020 Jun 04;8:468
pubmed: 32582718
Drugs. 2020 Dec;80(18):1929-1946
pubmed: 33068263
Science. 2020 Nov 20;370(6519):950-957
pubmed: 32972994
Cochrane Database Syst Rev. 2020 Aug 26;8:CD013705
pubmed: 32845525
Nat Microbiol. 2020 Apr;5(4):536-544
pubmed: 32123347
Biology (Basel). 2020 Oct 01;9(10):
pubmed: 33019595
Eur Rev Med Pharmacol Sci. 2020 Jun;24(12):7173-7191
pubmed: 32633414
J Clin Pathol. 2021 Aug;74(8):496-503
pubmed: 34049977
Mikrobiyol Bul. 2020 Jul;54(3):497-509
pubmed: 32755524

Auteurs

Leonardo Miscio (L)

Istituto Nazionale Tumori Di Napoli, IRCCS "G. Pascale", Naples, Italy. leonardo.miscio@istitutotumori.na.it.

Antonio Olivieri (A)

Gaboservice, Caserta, Italy.

Francesco Labonia (F)

Istituto Nazionale Tumori Di Napoli, IRCCS "G. Pascale", Naples, Italy.

Gianfranco De Feo (G)

Istituto Nazionale Tumori Di Napoli, IRCCS "G. Pascale", Naples, Italy.

Paolo Chiodini (P)

Università Degli Studi Della Campania Luigi Vanvitelli, Naples, Italy.

Giuseppe Portella (G)

Azienda Ospedaliera Universitaria "Federico II", Naples, Italy.

Luigi Atripaldi (L)

Azienda Ospedaliera dei Colli - PO Cotugno, Naples, Italy.

Roberto Parrella (R)

Azienda Ospedaliera dei Colli - PO Cotugno, Naples, Italy.

Rodolfo Conenna (R)

Azienda Ospedaliera dei Colli - PO Cotugno, Naples, Italy.

Franco Maria Buonaguro (FM)

Istituto Nazionale Tumori Di Napoli, IRCCS "G. Pascale", Naples, Italy.

Ernesta Cavalcanti (E)

Istituto Nazionale Tumori Di Napoli, IRCCS "G. Pascale", Naples, Italy.

Paolo Ascierto (P)

Istituto Nazionale Tumori Di Napoli, IRCCS "G. Pascale", Naples, Italy.

Gerardo Botti (G)

Istituto Nazionale Tumori Di Napoli, IRCCS "G. Pascale", Naples, Italy.

Attilio Bianchi (A)

Istituto Nazionale Tumori Di Napoli, IRCCS "G. Pascale", Naples, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH